2026 First-Quarter reported sales growth of 9.9% to $24.1 Billion with operational growth of 6.4%* and adjusted operational growth of 5.3%*
2026 First-Quarter earnings per share (EPS) of $2.14 and adjusted EPS of $2.70
Company increases 2026 guidance with estimated reported salesof $100.8 Billion or 7.0% at the midpoint, and adjusted EPS⁴of $11.55 or 7.1% at the midpoint
Solidifying path to double-digit growth by the end of the decade, with significant progress for patients with the approvals of ICOTYDE the first-and-only targeted oral peptide for plaque psoriasis, TECVAYLI plus DARZALEX FASPRO as early as second line for patients with relapsed/refractory multiple myeloma, VARIPULSE Pro in Europe with a new pulse sequence that is now 5 times faster, and TECNIS PureSee Intraocular Lens for U.S. Cataract Patients
Company announces planned Enterprise Business Review for December 8, 2026

Johnson & Johnson (NYSE:JNJ) today announced results for first-quarter 2026. "Johnson & Johnson had a strong start to 2026 and is delivering on its promise for a year of accelerated growth and impact," said Joaquin Duato, Chairman and Chief Executive Officer, Johnson & Johnson. "The depth and strength of our portfolio and pipeline is unrivaled and our relentless focus on innovation delivered multiple game-changing approvals this quarter, including ICOTYDE in the U.S. for moderate to severe plaque psoriasis and VARIPULSE Pro in Europe. These advancements have the potential to transform patient outcomes and create sustainable, long-term value for shareholders."

Overall financial results

	Q1
($ in Millions, except EPS)	2026		2025	% Change
Reported Sales		$24,062	$21,893	9.9%
Net Earnings		$5,235	$10,999	-52.4%
EPS (diluted)		$2.14	$4.54	-52.9%

	Q1
*Non-GAAP ($ in Millions, except EPS)**	2026		2025	% Change
Operational Sales^1,2				6.4%
Adjusted Operational Sales^1,3				5.3%
Adjusted Net Earnings^1,4		$6,614	$6,706	-1.4%
Adjusted EPS (diluted)^1,4		$2.70	$2.77	-2.5%
Free Cash Flow^5,6		~$1,500	$3,379

¹	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
²	Excludes the impact of translational currency
³	Excludes the net impact of acquisitions and divestitures and translational currency
⁴	Excludes intangible amortization expense and special items
⁵	Non-GAAP measure; defined as cash flow from operating activities, less additions to property, plant and equipment. Cash flow from operations, the most directly comparable GAAP financial measure, will be included in subsequent SEC filings.
⁶	First-quarter 2026 is estimated as of April 14, 2026
Note: values may have been rounded

Regional sales results

Q1				% Change
($ in Millions)	2026	2025	Reported	Operational^1,2	Currency	Adjusted Operational^1,3
U.S.	$13,330	$12,305	8.3%	8.3	-	6.2
International	10,732	9,588	11.9	3.9	8.0	4.0
Worldwide	$24,062	$21,893	9.9%	6.4	3.5	5.3

¹	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
²	Excludes the impact of translational currency
³	Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded

Segment sales results

Q1				% Change
($ in Millions)	2026	2025	Reported	Operational^1,2	Currency	Adjusted Operational^1,3
Innovative Medicine	$15,426	$13,873	11.2%	7.4	3.8	5.6
MedTech	8,636	8,020	7.7	4.6	3.1	4.7
Worldwide	$24,062	$21,893	9.9%	6.4	3.5	5.3

¹	Non-GAAP financial measure; refer to reconciliations of non-GAAP financial measures included in accompanying schedules
²	Excludes the impact of translational currency
³	Excludes the net impact of acquisitions and divestitures and translational currency
Note: values may have been rounded

First-Quarter 2026 segment commentary:

Operational sales* reflected below excludes the impact of translational currency.

Innovative Medicine

Innovative Medicine worldwide operational sales grew 7.4%*, with net acquisitions and divestitures positively impacting growth by 1.8% primarily due to CAPLYTA. Growth was driven primarily by DARZALEX, CARVYKTI, ERLEADA, and RYBREVANT/LAZCLUZE in Oncology, TREMFYA in Immunology, and SPRAVATO in Neuroscience. Growth was partially offset by an approximate (920) basis points impact from STELARA in Immunology, as well as IMBRUVICA in Oncology.

MedTech

MedTech worldwide operational sales grew 4.6%*, with divestitures negatively impacting growth by 0.1%. Growth was driven primarily by electrophysiology products, Abiomed, and Shockwave in Cardiovascular, as well as trauma in Orthopaedics.

Full-year 2026 guidance:

Johnson & Johnson does not provide GAAP financial measures on a forward-looking basis because the company is unable to predict with reasonable certainty the ultimate outcome of legal proceedings, unusual gains and losses, acquisition-related expenses, and purchase accounting fair value adjustments without unreasonable effort. These items are uncertain, depend on various factors, and could be material to Johnson & Johnson's results computed in accordance with GAAP.

($ in Billions, except EPS)

April 2026

January 2026

Adjusted Operational Sales^1,2

Johnson & Johnson reports Q1 2026 results, raises 2026 outlook